Overview
Adalvo, a global pharmaceutical company, announces the successful DCP approval for Liraglutide pre-filled pen, marking it as the first generic approval in the EU.
Victoza Pre-filled Pen: Indication
As a bioequivalent version of Victoza pre-filled pen, indicated for the treatment of type 2 diabetes, this peptide drug achieved global sales exceeding $4.8 billion in 2023, as reported by IQVIA.
Adalvo's Capability
The successful development of Liraglutide highlights Adalvo's capability to offer a diverse and comprehensive diabetes portfolio, encompassing both complex peptide injectables and small molecule oral treatments.
Our Commitment
Our commitment to providing access to high-quality differentiated products while simultaneously navigating manufacturing complexities reinforces Adalvo's position as a trusted leader in the pharmaceutical industry.
About Adalvo
- Adalvo is a global pharmaceutical company, and one of the leading B2B pharmaceutical companies in Europe, with commercial partnerships in more than 130 countries and over 140 commercial partners globally.
- The company’s declared purpose is to make a difference for patients all over the world, driven by our smart collaboration network and commitment to delivering the highest quality differentiated products and services to our partners.
